U.S. FDA approves KYGEVVI™ (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
Approved indication: KYGEVVI™ (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase…